Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To investigate the efficacy and safety of Telitacicept in patients with primary immunoglobulin A nephropathy (IgAN) and an estimated glomerular filtration rate (eGFR) of less than 35 ml/min/1.73m².
Twelve primary IgAN patients with eGFR <35 ml/min/1.73m² treated with Telitacicept were enrolled. Data including age, gender, 24-hour urinary total protein (UTP), and serum creatinine levels before and after treatment were collected, with a maximum follow-up duration of 24 weeks. UTP and eGFR were compared before and after treatment, and adverse events during follow-up were recorded.
All 12 patients had biopsy-proven IgAN, secondary causes were excluded, and all completed ≥12 weeks of Telitacicept treatment. The median age was 36 years, including 7 males (58%). All 12 patients (100%) were classified as Lee's grade V. The Oxford-MESTC scores indicated a high prevalence of mesangial hypercellularity and segmental glomerulosclerosis. Six patients (50%) concurrently received corticosteroid therapy. The initial dose of Telitacicept was 160 mg/week in 8 patients (67%) and 240 mg/week in 4 patients (33%). Baseline characteristics were: mean UTP 2.97 ± 1.65 g/d (mild proteinuria in 1 patient [8%], moderate in 7 [59%], severe in 4 [33%]); mean serum creatinine 257.25 ± 64.16 μmol/L; mean eGFR 25.09 ± 5.79 ml/min/1.73m². Following Telitacicept treatment, UTP showed a significant decrease at weeks 4, 8, 12, 16, 20, and 24, with values of 2.60 ± 1.64, 2.30 ± 1.55, 1.98 ± 1.35, 1.70 ± 1.05, 2.10 ± 1.49, and 1.89 ± 1.79 g/d, respectively. eGFR remained generally stable at these time points: 26.51 ± 5.59, 26.52 ± 6.32, 27.77 ± 6.37, 27.16 ± 8.49, 27.22 ± 7.29, and 26.63 ± 7.05 ml/min/1.73m². The percentage reduction in proteinuria at weeks 4, 8, 12, 16, 20, and 24 was 12%, 23%, 33%, 43%, 29%, and 36%, respectively. Telitacicept was well-tolerated by all patients. Apart from local injection reactions, two adverse events were recorded (one urinary tract infection and one pulmonary infection), both occurring in the group receiving concomitant corticosteroid therapy.
In IgAN patients with severely impaired renal function, Telitacicept demonstrated good tolerability and showed potential in reducing proteinuria and maintaining stable renal function.
